 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...7879808182838485868788...123124» |
- | lenvatinib / Generic mfg.
Journal, IO biomarker: Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. (Pubmed Central) - Jul 28, 2021
Among these, two (67%, 2/3) who had HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI carried a CTNNB-1 mutation, while all four patients who had HCC without iso-high intensity in the hepatobiliary phase of EOB-MRI did not carry the CTNNB-1 mutation. This study's findings have clinical implications for the detection and treatment of HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI.
- || Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal: Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma). (Pubmed Central) - Jul 28, 2021
They were subsequently treated with combined immunotherapy and TKI treatment, resulting in a near complete response within a very short time. Clinical responses were supported by in vitro testing of each patient's lymphocytic response to pembrolizumab after pre-exposure of target cancer cells to lenvatinib.
- || lenvatinib / Generic mfg.
Clinical, Journal: Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. (Pubmed Central) - Jul 27, 2021
We found a strong linear correlation between pre- and post-treatment tumor burden. Our results suggested a cut-off value for baseline tumor burden for long-term prognosis among patients treated with lenvatinib.
- ||||| vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD)
New P2 trial, Pan tumor: MK-7684A With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors MK-7684A con o sin otros tratamientos antineopl (EUDRACT) - Jul 27, 2021
P2, N=480, Ongoing, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- ||||| GI-101 / GI Innovation
New P1/2 trial, Metastases: KEYNOTE-B59: GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors (clinicaltrials.gov) - Jul 27, 2021
P1/2, N=374, Not yet recruiting, Sponsor: GI Innovation, Inc.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Metastases: A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Jul 26, 2021
P4, N=50, Completed, Sponsor: Eisai Pharmaceuticals India Pvt. Ltd
Our results suggested a cut-off value for baseline tumor burden for long-term prognosis among patients treated with lenvatinib. Active, not recruiting --> Completed
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: LITESPARK-016: Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) (clinicaltrials.gov) - Jul 26, 2021
P2, N=400, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical: Improvements were observed in the lenvatinib plus pembrolizumab arm for PFS, OS, & ORR in the multicenter, open-label, randomized study, phase 3 CLEAR trial. @ViktorGruenwald @ASCO #ASCO21 #kcsm https://t.co/RQtBAtF2PC (Twitter) - Jul 25, 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, FDA event: Glad to see FDA grant regular approval this week on the heels of the accelerated approval 9/17/2019. Pembrolizumab and lenvatinib for advanced endometrial carcinoma now a "permanent" option for our MS-stable patients. https://t.co/YrnuLwtU9B (Twitter) - Jul 23, 2021
- ||||| gefitinib / Generic mfg., lenvatinib / Generic mfg.
Clinical data: Just in @Nature by Drs. Haojie Jin & Rene Bernards Combined gefitinib and lenvatinib inhibits hepatic cancer in murine model by blocking EGFR feedback signal. Early clinical data promising. Clincal trial is ongoing. @helops79 https://t.co/bKWb7Ahk00 (Twitter) - Jul 23, 2021
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC (clinicaltrials.gov) - Jul 22, 2021
P1, N=50, Recruiting, Sponsor: Fudan University
- || lenvatinib / Generic mfg.
Retrospective data, Review, Journal: Letter to the editors on "Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials". (Pubmed Central) - Jul 22, 2021
We read the recent study "Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials" by Zhipeng Yan, et al. for the evaluation of lenvatinib in the treatment of radioiodine-refractory thyroid carcinoma.
- Xalkori (crizotinib) / Pfizer, Tabrecta (capmatinib) / Incyte, Novartis
[VIRTUAL] MET fusions as therapeutic targets in solid tumors () - Jul 22, 2021 - Abstract #ESMO2021ESMO_3044;
Careful bioinformatic evaluation is mandatory to select patients who may benefit from MET inhibitor treatment. Based on our findings we conclude that detection of MET fusions can be a useful enrichment of biomarker testing in solid tumors and MET inhibitors might be considered if standards of evaluation are considered.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Targeting FGFR signaling with FGFR inhibitor-based regimens: UCSD molecular tumor board experience () - Jul 22, 2021 - Abstract #ESMO2021ESMO_3024;
Most tumors with FGFR pathway abnormalities had co-genomic alterations. Targeting FGFR signaling achieved a clinical benefit rate of 35% (median duration= 14 months) in the pan-cancer setting.
- lenvatinib / Generic mfg.
[VIRTUAL] Health-related quality-of-life (HRQoL) analyses from study 211: A phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN) () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2995;
P2
These data combined with prior efficacy data support use of the LEN24 starting dose in pts with RR-DTC.. Mitchell, PhD, of Oxford PharmaGenesis Inc., Newtown, PA, USA, and was funded by Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] A phase II single-arm study of pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma (CKS): The PULSAR trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2817;
P2
Main inclusion criteria include: histologically confirmed diagnosis of CKS, and progression or inadequate response to ≥1 prior CT. Exclusion criteria include known human immunodeficiency virus (HIV) infection.
- lenvatinib / Generic mfg.
[VIRTUAL] Predicting the efficacy of lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC) using radiomics features of tumors extracted from baseline MRI () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2265;
P=N/A
Exclusion criteria include known human immunodeficiency virus (HIV) infection. Radiomics features from baseline MRI may serve as predictors for objective response to lenvatinib plus anti-PD-1 antibodies in uHCC patients before treatment initiation.
- lenvatinib / Generic mfg.
[VIRTUAL] Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Updated results from a multi-center prospective cohort study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2262;
P=N/A
In the expanded cohorts, adjuvant lenvatinib in combination with TACE showed prolonged DFS over TACE alone for patients with high recurrence risk after resection. And there were no unexpected safety signals in the combination group.
- Avastin (bevacizumab) / Roche, KN046 / Alphamab
[VIRTUAL] KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Preliminary efficacy and safety results of a prospective phase II trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2255;
P2
Background: In IMbrave 150 study combo treatment of PD-L1 inhibitor (Atezolizumab) with VEGFR inhibitor（Bevacizumab）prolonged the overall survival dramatically in HCC. KN046+Lenvatinib showed promising antitumor activity with relatively high ORR and a tolerable safety profile in 1st line HCC treatment.
- cisplatin / Generic mfg., lenvatinib / Generic mfg.
[VIRTUAL] Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2254;
Len+CDDP yielded very favorable ORR and overall survival, and was well-tolerated in pts with advanced HCC. Further evaluation of this regimen in a phase III trial is warranted.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111 () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2129;
P1b/2
Cappelli, PhD, CMPP, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- quavonlimab/pembrolizumab (MK-1308A) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD)
[VIRTUAL] Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC) () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2056;
P3
Secondary end points are objective response rate, duration of response, patient-reported outcomes, and safety. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and Eisai Inc., Woodcliff Lake, NJ, USA.
- Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
[VIRTUAL] Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2001;
P3
In pts with aRCC, L + P demonstrated efficacy benefits over S in pts with/without adverse prognostic features, including sarcomatoid histology, bone and/or liver metastasis, and no prior nephrectomy. Only 15% of pts needed high-dose corticosteroids for irAEs.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Phase Ib/II trial of pembrolizumab (pembro) + lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1989;
P1/2
Secondary end points include time to PSA progression, ORR, and rPFS per PCWG3-modified RECIST v1.1 by BICR; DOR and DCR per RECIST v1.1 and PCWG3-modified RECIST v1.1 by BICR; and OS. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- lenvatinib / Generic mfg.
[VIRTUAL] Real-life monocentric, retrospective study on efficacy and tolerability of lenvatinib (Len) in patients (pts) with advanced radioactive iodine–refractory differentiated thyroid cancer (rDTC) () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1924;
Higher PFS (and OS) observed in this study, compared with other Clinical trials, is probably due to fewer pts needing dose reductions, shorter time of treatment interruption and fewer pts with cancer-related symptoms at Len initiation. Hence, a multidisciplinary approach could lead to establish appropriate timing for Len initiation and may allow the early detection and better management of AE.
- BI 836880 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1886;
P1
Part 2 has 7 cohorts: metastatic (m) NSCLC after checkpoint inhibitor (CPI) monotherapy (Cohort A); mNSCLC after chemotherapy (CT) + CPI (Cohort B); mSCLC after CT ± CPI (Cohort C); recurrent GBM (1st and 2nd recurrence; Cohort D); immunotherapy-resistant m-melanoma (Cohort E); HCC after prior sorafenib or lenvatinib (Cohort F); and previously untreated unresectable HCC (Cohort G). BI 836880 plus ezabenlimab had a manageable safety profile, with preliminary activity in a range of tumour types.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): Phase III LEAP-017 study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1868;
P2, P3
Approximately 434 patients will be enrolled. Kulak, PhD, and Doyel Mitra, PhD, CMPP, of ApotheCom (Yardley, PA, USA).
- lenvatinib / Generic mfg.
[VIRTUAL] The characterization of tumors associated with the antitumor activity of lenvatinib plus anti-PD-1 antibody combination therapy in a mouse syngeneic model panel () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1410;
Kulak, PhD, and Doyel Mitra, PhD, CMPP, of ApotheCom (Yardley, PA, USA). In this study, we found that MVD combined with GEP might be the important predictive biomarkers reflecting the antitumor activities of lenvatinib monotherapy and lenvatinib plus anti-PD-1 combination therapy.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy (Channel 5) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1294;
P3
At the final analysis of COSMIC-311 with longer follow-up, C maintained its superior efficacy vs P with a manageable safety profile in pts with previously treated RAIR-DTC. The PFS benefit was consistent with the interim analysis and irrespective of prior VEGFR-targeted therapy.).
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775) (Channel 5) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1275;
P3
LEN + pembro provided meaningful efficacy improvements in pts with previously treated advanced EC across all histologies (including difficult to treat histologies), and irrespective of prior (neo)adjuvant tx, and platinum-free interval (PFI) from most recent platinum tx. Pts with 1 prior line of platinum had greater benefit than those with ≥1 line, supporting early use of LEN + pembro.
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, FDA event: FDA Approves Lenvatinib/Pembrolizumab for Select Patients With Advanced Endometrial Cancer https://t.co/GUtCHjNH28 via @targetedonc (Twitter) - Jul 22, 2021
- ||| Enrollment open, Combination therapy, Monotherapy: Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (clinicaltrials.gov) - Jul 22, 2021
P1b/2, N=80, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Pts with 1 prior line of platinum had greater benefit than those with ≥1 line, supporting early use of LEN + pembro. Not yet recruiting --> Recruiting
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) (clinicaltrials.gov) - Jul 22, 2021
P2, N=120, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. (Pubmed Central) - Jul 22, 2021
Not yet recruiting --> Recruiting No abstract available
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply. (Pubmed Central) - Jul 22, 2021
No abstract available No abstract available
- ||| lenvatinib / Generic mfg.
EGFR activation limits the response of liver cancer to lenvatinib https://t.co/T0zLed3ALV (Twitter) - Jul 21, 2021
- | Bosulif (bosutinib) / Pfizer, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Quinoline-based compounds with potential activity against drug-resistant cancers. (Pubmed Central) - Jul 21, 2021
The present short review article provides an overview about the recent advances of quinoline-based compounds with potential activity against drug-resistant cancers. The structure-activity relationship and mechanisms of action are also discussed.
- || lenvatinib / Generic mfg., irinotecan / Generic mfg.
P2 data, Journal: Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503). (Pubmed Central) - Jul 21, 2021
The structure-activity relationship and mechanisms of action are also discussed. Lenvatinib showed promising clinical activity and was tolerated in patients with metastatic colorectal cancer after failure of standard chemotherapies.
- || lenvatinib / Generic mfg.
Clinical, Journal: Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. (Pubmed Central) - Jul 21, 2021
Late treatment-related AEs rarely occurred. Oligoprogressive and slowly progressive disease can be managed without treatment withdrawal as long as there are some clinical benefits.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, IO biomarker: Clinical trial of combined therapy with pembrolizumab and lenvatinib for patients with classic Kaposi sarcoma treated with at least one previous line of chemioterapy. Studio clinico della terapia combinazione di pembrolizumab e lenvatinib nei pazienti con sarcoma di Kaposi classico trattato con una precedente chemioterapia. (EUDRACT) - Jul 20, 2021
P2, N=25, Ongoing, Sponsor: FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT (clinicaltrials.gov) - Jul 18, 2021
P=N/A, N=171, Recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date: PLANE-PC: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (clinicaltrials.gov) - Jul 15, 2021
P2, N=50, Recruiting, Sponsor: Ulka Vaishampayan
Oligoprogressive and slowly progressive disease can be managed without treatment withdrawal as long as there are some clinical benefits. Not yet recruiting --> Recruiting | Trial completion date: Jan 2025 --> Jul 2023 | Trial primary completion date: Jan 2024 --> Oct 2022
- |||||| Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
Clinical: The combination of lenvatinib plus pembrolizumab is not only efficacious, but has also proven to improve HRQoL vs sunitinib in the first line treatment of patients with advanced RCC. @motzermd @sloan_kettering @ASCO #ASCO21 #kcsm https://t.co/sMhbCnyMdw (Twitter) - Jul 15, 2021
- lenvatinib / Generic mfg.
[VIRTUAL] The role of first-line monotherapy in a uHCC combination market () - Jul 15, 2021 - Abstract #ILCA2021ILCA_44;
A panel of leading experts will discuss the role of LENVIMA® (lenvatinib) monotherapy in a rapidly evolving treatment landscape, followed by a live Q&A. With combination therapies expected to become the standard of care in first-line uHCC, our panel will cover a variety of topics including patient selection, clinical considerations, and the latest realworld evidence.
- || lenvatinib / Generic mfg.
Clinical, Review, Journal: Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. (Pubmed Central) - Jul 15, 2021
No significant change in lenvatinib pharmacokinetics has been observed with other patient-related factors and very few data are available on lenvatinib pharmacogenetics. Lenvatinib can be administered orally regardless of food and no clinically relevant drug-drug interactions have been reported.
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical: Robert J. Motzer, MD, discusses the efficacy & HRQoL benefits of lenvatinib/pembrolizumab in patients w/ advanced RCC, & projected where the regimen might fit into the treatment paradigm. @motzermd @sloan_kettering @ASCO #ASCO21 #kcsm https://t.co/hZgmpjkdPj (Twitter) - Jul 14, 2021
- || paclitaxel / Generic mfg., lenvatinib / Generic mfg.
Really interesting results and work by @FBackesMD and the @OSUCCC_James Phase I evaluation of lenvatinib and weekly paclitaxel https://t.co/P4ynEfmuqU (Twitter) - Jul 14, 2021
- |||| paclitaxel / Generic mfg., lenvatinib / Generic mfg.
Clinical: Congrats to @FBackesMD for this phase 1 data from @OSUCCC_James Clinical trials are so important to improve our #cancer outcomes and achieve our goal to #endcancer Phase I evaluation of lenvatinib and weekly paclitaxel in patients wit... https://t.co/pBER47FKO8 (Twitter) - Jul 14, 2021
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors (clinicaltrials.gov) - Jul 14, 2021
P2, N=35, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Lenvatinib can be administered orally regardless of food and no clinically relevant drug-drug interactions have been reported. Trial primary completion date: Dec 2021 --> Dec 2022
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
Journal, Checkpoint inhibition: Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates. (Pubmed Central) - Jul 14, 2021
In sorafenib-experienced patients, nivolumab + ipilimumab (ORR 32%) provided the highest ORR among ICI-based regimens. Our findings emphasize high therapeutic potential of ICI-based therapies in patients with advanced hepatocellular carcinoma, though further studies are required to further validate and define their role in this context.